| Produktname | Linagliptin |
|---|---|
| CAS-Nummer | 668270-12-0 |
| Molekülformel | C25H28N8O2 |
| Molekulargewicht | 472.54 g/mol |
| Aussehen | Weißes bis cremefarbenes kristallines Pulver |
| Analyse (HPLC) | ≥99,01 TP3T |
| Trocknungsverlust | ≤0,5% |
| Verbrennungsrückstand | ≤0,1% |
| Schwermetalle | ≤ 10 ppm |
| Schmelzpunkt | 196-202°C |
| Spezifische Rotation | [α]D20 = +50° to +56° (c=1, methanol) |
Brauchst du Hilfe? Kontaktieren Sie unser Team
Linagliptin is the DPP-4 inhibitor that doesn’t need a dose adjustment for kidney or liver function – and that’s a big deal for type 2 diabetes patients who often have comorbidities. Unlike many of its peers, it’s cleared primarily via bile and gut, so it’s a safer bet for long-term use in renally impaired patients. For formulators, that means a competitive edge in a crowded market: you can offer a once-daily, 5 mg tablet that works reliably without the monitoring headaches.
We supply linagliptin as a high-purity, crystalline API that meets or exceeds pharmacopoeial standards. Every batch is rigorously tested and shipped with a full COA, so you can move from development to production with confidence.
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese